Benabbad I, et al. - This trial inspected if delaying pubertal progression could increase near-adult height (NAH) in growth hormone (GH)-treated patients with idiopathic short stature (ISS). Enrollees were randomised to GH with leuprorelin. It was reported that statistical comparison of NAH standard deviation score (SDS) between the 2 cohorts was not possible owing to premature discontinuation of treatments. Findings disclosed that during the first 2-3 years of treatment, patients treated with the combination grew more slowly than those receiving GH alone. Both groups reported similar mean NAH SDS. It was determined that there were no new GH-related safety concerns. Yielded data detected a potentially deleterious effect of combined treatment on bone fracture incidence.